

Combined population genomic screening for three high-risk conditions in Australia: a modelling study



Paul Lacaze,^{a,n,*} Clara Marquina,^{b,n} Jane Tiller,^a Adam Brotchie,^a Yoon-Jung Kang,^c Melissa A. Merritt,^c Robert C. Green,^d Gerald F. Watts,^{e,m} Kristen J. Nowak,^{f,g} Ranjit Manchanda,^{h,i} Karen Canfell,^c Paul James,^{j,k,l} Ingrid Winship,^{k,l} John J. McNeil,^a and Zanfina Ademi^{a,b,**}



^aSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia

^bHealth Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia

^cThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 2011, Australia

^dMass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School, Boston, MA, 02114, USA

^eSchool of Medicine, University of Western Australia, Perth, WA 6009, Australia

^fPublic and Aboriginal Health Division, Western Australia Department of Health, East Perth, WA, 6004, Australia

^gCentre for Medical Research, The University of Western Australia, Crawley, WA, 6009, Australia

^hWolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

ⁱDepartment of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK

^jParkville Familial Cancer Centre, Peter McCallum Cancer Centre, Melbourne, VIC, 3000, Australia

^kDepartment of Genomic Medicine, Royal Melbourne Hospital City Campus, Parkville, VIC, 3050, Australia

^lDepartment of Medicine, University of Melbourne, Parkville, VIC, 3050, Australia

^mDepartments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, WA, 6001, Australia

Summary

Background No previous health-economic evaluation has assessed the impact and cost-effectiveness of offering combined adult population genomic screening for multiple high-risk conditions in a national public healthcare system.

Methods This modeling study assessed the impact of offering combined genomic screening for hereditary breast and ovarian cancer, Lynch syndrome and familial hypercholesterolaemia to all young adults in Australia, compared with the current practice of clinical criteria-based testing for each condition separately. The intervention of genomic screening, assumed as an up-front single cost in the first annual model cycle, would detect pathogenic variants in seven high-risk genes. The simulated population was 18–40 year-olds (8,324,242 individuals), modelling per-sample test costs ranging AU\$100–\$1200 (base-case AU\$200) from the year 2023 onwards with testing uptake of 50%. Interventions for identified high-risk variant carriers follow current Australian guidelines, modelling imperfect uptake and adherence. Outcome measures were morbidity and mortality due to cancer (breast, ovarian, colorectal and endometrial) and coronary heart disease (CHD) over a lifetime horizon, from healthcare-system and societal perspectives. Outcomes included quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER), discounted 5% annually (with 3% discounting in scenario analysis).

Findings Over the population lifetime (to age 80 years), the model estimated that genomic screening per-100,000 individuals would lead to 747 QALYs gained by preventing 63 cancers, 31 CHD cases and 97 deaths. In the total model population, this would translate to 31,094 QALYs gained by preventing 2612 cancers, 542 non-fatal CHD events and 4047 total deaths. At AU\$200 per-test, genomic screening would require an investment of AU\$832 million for screening of 50% of the population. Our findings suggest that this intervention would be cost-effective from a healthcare-system perspective, yielding an ICER of AU\$23,926 (~£12,050/€14,110/US\$15,345) per QALY gained over the status quo. In scenario analysis with 3% discounting, an ICER of AU\$4758/QALY was obtained. Sensitivity analysis for the base case indicated that combined genomic screening would be cost-effective under 70% of simulations, cost-saving under 25% and not cost-effective under 5%. Threshold analysis showed that genomic screening would be cost-effective under the AU\$50,000/QALY willingness-to-pay threshold at per-test costs up to AU\$325 (~£164/€192/US\$208).

eClinicalMedicine
2023;66: 102297
Published Online 8
November 2023
<https://doi.org/10.1016/j.eclinm.2023.102297>

*Corresponding author. School of Public Health and Preventive Medicine, Monash University Level 5, 553 St Kilda Rd, Melbourne, 3004, Australia.

**Corresponding author. Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.

E-mail addresses: paul.lacaze@monash.edu (P. Lacaze), zanfina.ademi@monash.edu (Z. Ademi).

@PaulLacaze (P. Lacaze), @ZANFINA (Z. Ademi).

ⁿCo-first authors.

Interpretation Our findings suggest that offering combined genomic screening for high-risk conditions to young adults would be cost-effective in the Australian public healthcare system, at currently realistic testing costs. Other matters, including psychosocial impacts, ethical and societal issues, and implementation challenges, also need consideration.

Funding Australian Government, Department of Health, Medical Research Future Fund, Genomics Health Futures Mission (APP2009024). National Heart Foundation Future Leader Fellowship (102604).

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Population screening; Cost-effectiveness analysis; Health-economic evaluation; Genomic testing; Public health; Prevention; Genomics

Research in context

Evidence before this study

Previous cost-effectiveness analyses of adult population genomic screening have mostly focused on single condition screening, rather than a combined approach for multiple conditions. We searched PubMed and MEDLINE for articles published up to May 10th 2023 to identify economic evaluations of population genomic screening, using search terms “population genomic screening”, “population-based genetic testing”, “cost-effectiveness analysis”, “health-economic evaluation” and “modelling study”. The literature review identified 14 studies. However, none had assessed the impact of combined genomic screening in a national public healthcare system, for ‘tier 1’ medically actionable conditions designated by the US CDC (hereditary breast and ovarian cancer, Lynch syndrome, familial hypercholesterolaemia). One study assessed such screening in the US system.

Added value of this study

Before this study, there was a knowledge gap regarding the feasibility of offering combined population genomic screening for the above conditions in a national public healthcare

system setting, with a lack of evidence to inform policy. This study addresses the knowledge gap by modelling combined population genomic screening for all adults aged 18–40 years in the Australian public healthcare system, demonstrating an improvement in the overall cost-effectiveness of combined population genomic screening, versus the status quo of criteria-based genetic testing or screening for individual conditions separately. The modelling is accompanied by a real-world pilot study in Australia of population genomic screening for the same conditions involving 10,000 adults aged 18–40 years from the general population.

Implications of all the available evidence

This modelling study provides evidence to inform screening policy in Australia and other jurisdictions, suggesting that offering combined population genomic screening to young adults would be cost-effective in a national public healthcare system. This comes at a time when various healthcare systems and providers around the world are considering the implementation of adult population genomic screening.

Introduction

Adult population genomic screening presents an immediate opportunity for public health, particularly to enable the early detection, diagnosis, early intervention, and prevention of cancer and heart disease caused by high-risk inherited genomic conditions.^{1–3} Around 1 in 75 people (1.3% of the general population^{4–8} across diverse ancestries⁹) carry pathogenic or likely pathogenic germline variants for three high-risk medically actionable conditions caused by single DNA variants: hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS) and familial hypercholesterolemia (FH). These monogenic conditions have been prioritised by the US Centers for Disease Control and Prevention (CDC) as leading candidates for adult population genomic screening⁴ owing to their prevalence, high

penetrance of disease-associated genes, and availability of evidence-based risk-management options.^{2,3}

The proven risk-management interventions for these conditions can be lifesaving, especially if made available early. Women identified with HBOC pathogenic variants (hereafter referred to as PVs) including in the *BRCA1* and *BRCA2* genes can access breast imaging (mammography, MRI and/or ultrasound), risk-reducing bilateral mastectomy (RRBM) and salpingo-oophorectomy (RRSO) to reduce breast¹⁰ and ovarian^{11,12} cancer risk. Due to the serious nature of these interventions and fertility implications, the optimal age to offer genomic screening must be carefully considered. For Lynch syndrome, aspirin use and regular colonoscopy can reduce colorectal cancer risk,¹³ and hysterectomy with bilateral salpingo-oophorectomy

can reduce endometrial and ovarian cancer risk.¹⁴ For FH, statins and other cholesterol-lowering agents can markedly reduce the risk of premature coronary heart disease.^{15,16}

Despite the availability of these multifaceted effective risk-reducing strategies, detection rates for these inherited conditions in the general population remain very low, largely owing to the narrow eligibility criteria for publicly-funded genetic testing.^{17,18} In most countries, clinical criteria-based genetic testing for these conditions is restricted to individuals with a previous diagnosis and/or strong family history of disease, and is rarely offered to young, unselected adults. This restrictive approach is known to miss up to 90% of high-risk PV carriers in the general population, representing an unmet need and missed opportunity in preventive healthcare.^{15,18–20} In the UK, in 2018 it was estimated that only 2.5% of female *BRCA1* and *BRCA2* PV carriers had been identified, despite over 25 years of clinical genetic testing and cascade screening in affected families.¹⁸ This and similar findings in other countries^{4,20} indicate that the current criteria-based testing model is ineffective and not maximizing the preventative potential of genomics.

The alternative strategy of criteria-free population genomic screening for these conditions (i.e. offering preventive testing for a limited set of high-risk genes to unselected adults from the general population) has much promise.^{2,17,21,22} Previous cost-effectiveness analyses suggest that single-condition genomic screening for HBOC or FH alone may already be cost-effective in countries with a national public healthcare system, including Australia^{23,24} and the UK.^{25,26} However, results from the USA^{27–29} and other countries^{26–30} vary, not always suggesting cost-effectiveness for single-condition screening. Other matters also need consideration, including the psychosocial impact of genomic screening, and the ethical and societal issues. A recent study found combined screening for HBOC, LS and FH in the USA is likely to be cost-effective, if offered to 30 year-olds with low-cost testing (<US\$300).³¹ However, the USA is not supported by a national public healthcare system to deliver such genomic screening across the general population, raising concerns about equity of access. In Australia, by contrast, there is a national public healthcare system with implemented population screening programs available to individuals from the general population, funded by the Australian Government and guided by the national Population-Based Screening Framework. Further, the real-world feasibility of population genomic screening in Australia is being piloted in *DNA Screen* — a national pilot study offering combined screening for HBOC, LS and FH to 10,000 adults aged 18–40 years from the general population.¹⁷ The feasibility of genomic screening is also being evaluated in the PROTECT-C study in the UK public healthcare system.^{21,22} In the present modelling study,

we assess the cost-effectiveness and impact of offering combined genomic screening for HBOC, LS and FH to all adults aged 18–40 years via the Australian public healthcare system to inform future screening policy.


Methods

Model overview

We designed three decision analyses in combination with Markov models for five different disease outcomes caused by PVs in high-risk genes associated with HBOC (*BRCA1* and *BRCA2* genes, breast and ovarian cancer; Model 1); LS (*MLH1* and *MHS2* genes, colorectal cancer in men; colorectal and endometrial cancer in women; Model 2); and FH (*LDLR*, *APOB* and *PCSK9* genes, coronary heart disease (CHD), Model 3). The genes *PALB2* (HBOC) and *MHS6* (LS) were not included in the models because of the lack of age-adjusted risk data published for these genes at the time of analysis. For methodological details of each individual model, including model populations, structures, transition probabilities, health states, interventions and risk-reduction strategies, utilities and costs, see the [Supplementary Materials](#).

We first modelled each condition separately (Models 1–3), with events from each model considered mutually exclusive, then combined all models to generate the final results (Combined Model). Each individual model used decision trees followed by cohort multistate transition models (i.e. a cohort transitions from mutually exclusive health states based on given transition probabilities) to compare the health and economic outcomes of two different testing strategies for identifying PV carriers (Fig. 1). Strategy 1 (comparator: the status quo in Australia of criteria-based genetic testing for each condition separately) that assumed current detection rates for each condition individually are 10% (although real detection rates are likely to be far lower⁶). Strategy 2 (intervention: combined population genomic screening for all three conditions) that assumed a 100% detection rate for PV carriers in the modelled population for the base case (at 50% testing uptake and with 100% test sensitivity or specificity). These parameters were varied in sensitivity analyses. For both strategies, the modelled population for the base-case analysis included all Australians aged 18–40 years. We assumed genomic screening was delivered to the whole participating population during the first annual cycle of the model (rather than delivered over a period of several years).

Using life-table modeling (cohort modelling stratifying the population by age and single year of age and assigning sex- and age-specific probabilities), our analysis captured the estimated morbidity and mortality for high-risk PV carriers in the modelled population, identified using either strategy, over a lifetime horizon up to 80 years of age. We assumed all PV carriers (identified through either strategy) would receive post-test genetic counselling and access to standard-of-care risk



Abbreviations: **M**, Markov model.

Fig. 1: Schematic: Decision tree of population genomic screening versus the status quo. The combined model used decision trees followed by cohort multistate transition models to compare the health and economic outcomes of two different testing strategies for the detection of pathogenic variant (PV) carriers for hereditary breast and ovarian cancer (*BRCA1* and *BRCA2* genes), Lynch syndrome (*MLH1* and *MHS2* genes) and familial hypercholesterolemia (*LDLR*, *APOB* and *PCSK9* genes). Strategy 1 (the comparator) is the status quo in Australia of criteria-based genetic testing for each condition separately. Strategy 2 (the intervention) is combined population genomic screening for the three conditions combined in 18–40-year-olds.

management and ongoing surveillance and interventions, the costs of which were accounted for in the model. Risk-reducing interventions followed current Australian guidelines^{15,32} with assumed uptake rates for individual interventions based on published studies (see Table 1). For individual Markov model schematics, see Fig. 2.

The primary outcome of the model was the combined incremental cost-effectiveness ratio (ICER), which was defined as a cost per quality-adjusted life year (QALY) gained, using a willingness-to-pay (WTP) threshold of AU\$50,000/QALY.⁶⁷ Secondary outcomes included years of life lived, and the number of detrimental events (i.e. fatal and non-fatal breast cancer, ovarian cancer, colorectal cancer and endometrial cancer; and fatal and non-fatal CHD) averted through the implementation of population genomic screening. The model accounted for participation in current Australian population-based cancer screening programs in the status-quo and intervention arms, based on current eligibility criteria and uptake rates for these programs which begin at older ages (see Table 1). For the base-case analysis, the model adopted a healthcare-system perspective, including a societal perspective in the scenario analysis, with all outcomes discounted by 5% annually per standard practice in Australia (varied to 3% in scenario analysis).

Model population

The model population was based on age- and sex-specific data from the Australian Bureau of Statistics in June 2020⁶⁸ and included all Australians aged 18–40 years in the decision-analysis models (8,324,242 individuals). Of this population, 50% were assumed to uptake genomic screening during the first cycle of the model, resulting in 4,162,121 persons screened from the year 2023 onwards. The population genetic prevalence of each condition (i.e. the proportion of individuals in the general population who carry high-risk PVs for the condition) was estimated based on published studies: HBOC (*BRCA1* and *BRCA2* PVs) = 0.004 (~1 in 225),³⁶ LS (*MLH1* and *MSH2* PVs) = 0.00086 (~1 in 1160)⁶ and FH (*LDLR*, *PCSK9* and *APOB* PVs) = 0.004 (~1 in 250).⁸ These values were varied in the sensitivity analyses.

Risk and risk-reducing strategies


For HBOC, we estimated the annualized, age-specific risk of breast or ovarian cancer in female PV carriers, compared with women in the general population.⁷ Intensive breast cancer surveillance in detected PV carriers was assumed to follow current guidelines (i.e. an annual MRI and ultrasound from 30 years of age until death) with an assumed uptake of 89% and mortality hazard ratio (HR) of 0.13 with a 95% confidence

Input parameter	Base-case	Range	Distribution	Source
General parameters				
Uptake of population genomic screening	50%	25–100%	Log-normal	Assumption
Proportion of pathogenic variant (PV) carriers detected in the status-quo cohort (based on current rates of clinical criteria-based genetic testing)	10%	±15%	Log-normal	Assumption
Cost per test in the population genomic screening (intervention) cohort	AU\$200	AU\$100–AU\$1200	Gamma	Assumption
Cost per clinical diagnostic genetic test in the status-quo cohort	AU\$1200	Fixed	Fixed	MSAC #73296, #73354, #73352 ³³
Cost of clinical diagnostic confirmation testing and post-test genetic counseling	AU\$539	±25%	Gamma	MBS #133, MSAC #73297, MSAC #1504 ³³
Cost per non-cancer death	AU\$3394	±25%	Gamma	AR-DRG ³⁴
Specificity of DNA screening	100%	70–100%	Log-normal	Assumption
Sensitivity of DNA screening	100%	70–100%	Log-normal	Assumption
Utility weights for the health state “Alive, no disease”	Age- and sex-specific (Table S2.1)	Age and sex-specific	Beta	McCaffrey et al. ³⁵
Breast and ovarian cancer (screening for the BRCA1 and BRCA2 genes)				
Population prevalence of BRCA1 and BRCA2 pathogenic variants (PV)	0.004	0.004–0.006	Log-normal	Van Hout et al. ³⁶
BC incidence, general population	Age-specific (Table S3.3)	±15%	Log-normal	AIHW ³⁷
OC incidence, general population	Age-specific (Table S3.3)	±15%	Log-normal	AIHW ³⁷
BC incidence in BRCA1 and BRCA2 PV carriers (weighted average)	Age-specific (Table S3.3)	±15%	Log-normal	Kuchenbaecker et al. ⁷
OC incidence in BRCA1 and BRCA2 PV carriers (weighted average)	Age-specific (Table S3.3)	±15%	Log-normal	Kuchenbaecker et al. ⁷
Annual probability of remission for BC	0.37	±15%	Log-normal	AIHW ³⁷
Annual probability of remission for OC	0.12	±15%	Log-normal	AIHW ³⁷
% uptake of RRM	57.9%	±15%	Log-normal	Marcinkute et al. ³⁸
Starting age for RRM	40 years	Fixed	Fixed	Marcinkute et al. ³⁸
% uptake of RRSO	78.6%	±15%	Log-normal	Marcinkute et al. ³⁸
Average age for RRSO	45 years	Fixed	Fixed	Marcinkute et al. ³⁸
BC risk reduction after RRM (HR)	0.061	0.02–0.20	Beta	Marcinkute et al. ³⁸
OC risk reduction after RRSO (HR)	0.21	0.12–0.39	Beta	Domcheck et al. ¹⁰
CHD risk increase after RRSO (HR)	1.03	1.00–1.06	Log-normal	Mytton et al. ³⁹
BreastScreen uptake (standard of care breast cancer screening program)	55%	±15%	Log-normal	AIHW ³⁷
Starting age for BreastScreen	50 years	Fixed	Fixed	AIHW ³⁷
BC intensive screening uptake (for detected PV carriers only)	89%	81–100%	Log-normal	Rowley et al. ²⁰
Starting age of BC intensive screening	30	Fixed	Fixed	EviQ guidelines ³²
Mortality reduction in BC from standard screening (RR)	0.75	0.69–0.81	Beta	Myers et al. ⁴⁰
Mortality reduction in BC from intensive screening (RR)	0.13	0.032–0.53	Beta	Evans et al. ⁴¹
Cost per MRI	AU\$690	±25%	Gamma	AR-DRG ³⁴
Cost per mammogram	AU\$92	±25%	Gamma	MBS #59303 ³³
Cost per RRM (with breast reconstruction)	AU\$15,586	±25%	Gamma	AR-DRG ³⁴
Cost per RRSO	AU\$8621	±25%	Gamma	AR-DRG ³⁴
Cost per BC case in the initial phase (first year)	AU\$38,253	±25%	Gamma	Goldsbury et al. ⁴²
Cost per BC case in the continuing phase (annually)	AU\$4222	±25%	Gamma	Goldsbury et al. ⁴²
Cost per fatal BC case	AU\$40,531	±25%	Gamma	Goldsbury et al. ⁴²
Cost per OC case in the initial phase (first year)	AU\$58,734	±25%	Gamma	Gordon et al. ⁴³
Cost per OC case in the continuing phase (annually)	AU\$4696	±25%	Gamma	Goldsbury et al. ⁴²
Cost per fatal OC case	AU\$52,195	±25%	Gamma	Goldsbury et al. ⁴²
Utility weight BC in intensive screening (adjusted for cancer stages at the time of diagnosis)	0.85	±19% (SD)	Beta	Rautalin et al. ⁴⁴ and Warner et al. ⁴⁵
Utility weight BC in standard screening (adjusted for cancer stages at the time of diagnosis)	0.83	±19% (SD)	Beta	Rautalin et al. ⁴⁴ and Warner et al. ⁴⁵
Utility weight OC	0.69	±16% (SD)	Beta	Al-Dakkak et al. ⁴⁶ & Pickard et al. ⁴⁷
Utility weight post-BC health state	0.87	±16% (SD)	Beta	Pickard et al. ⁴⁷
Utility weight post-OC health state	0.77	±16% (SD)	Beta	Pickard et al. ⁴⁷
Utility RRM	0.88	±22% (SD)	Beta	Grann et al. ⁴⁸
Utility RRSO	0.95	±10% (SD)	Beta	Grann et al. ⁴⁸

(Table 1 continues on next page)

Input parameter	Base-case	Range	Distribution	Source
(Continued from previous page)				
Endometrial and colorectal cancer (screening for the MLH1 and MHS2 genes)				
Population prevalence of MLH1 and MHS2 pathogenic variants	0.00086	±15%	Log-normal	Win et al. ⁶
CRC incidence, general population	Age- and sex-specific (Table S4.1)	±15%	Log-normal	AIHW ³⁷
EC incidence, general population	Age- and sex-specific (Table S4.2)	±15%	Log-normal	AIHW ³⁷
CRC incidence, MLH1 and MHS2 PV carriers	Age- and sex-specific (Table S4.3)	±15%	Log-normal	Jenkins et al. ⁴⁹
EC incidence, MLH1 and MHS2 PV carriers (annual)	0.007	±15%	Log-normal	Lynch Syndrome Australia ¹⁹
% uptake of RRH	71%	±15%	Log-normal	Meiser et al. ⁵⁰
EC risk reduction after RRH	0.00	Fixed	Fixed	Schmeler et al. ⁵¹
Average age for RRH in MLH1 and MSH2 PV carriers	40 years	–	Fixed	Meiser et al. ⁵⁰
CRC incidence risk reduction by annual colonoscopy	0.85	±15%	Beta	Cancer Council Australia ⁵²
CRC mortality risk reduction by annual colonoscopy	0.85	±15%	Beta	Cancer Council Australia ⁵²
% uptake annual colonoscopy in detected PV carriers	87%	75–100%	Log-normal	Meiser et al. ⁵⁰
Starting age on annual colonoscopy in detected PV carriers	25 years	20–30 years	Fixed	Australian Government Department of Health ⁵³
iFOBT-based screening starting age (undetected PV carriers)	50 years	45–55	Fixed	Cancer Council Australia ⁵²
iFOBT-based screening uptake, males	42%	±15%	Log-normal	Cancer Council Australia ⁵²
iFOBT-based screening uptake, females	45%	±15%	Log-normal	Cancer Council Australia ⁵²
CRC risk reduction by chemoprevention (daily low-dose aspirin) (RR)	0.65	0.43–0.97	Beta	Burn et al. ⁵⁴
Starting age for chemoprevention in detected PV carriers	25 years	20–30	Fixed	Australian Government Department of Health ⁵³
% uptake of chemoprevention in detected PV carriers	87%	±15%	Log-normal	Meiser et al. ⁵⁰
Risk of gastrointestinal bleeding with aspirin	1.15	1.11–1.20	Log-normal	Shami et al. ⁵¹
iFOBT costs (biennial)	AU\$40	±25%	Gamma	Australian Government Department of Health ⁵³
Colonoscopy cost (annual or after positive iFOBT test)	AU\$1300	±25%	Gamma	Australian Government Department of Health ⁵³
Low-dose aspirin (annual costs)	AU\$139	±25%	Gamma	PBS ⁵⁵
Cost per CRC case in the initial phase (first year) (adjusted for disease stage at diagnosis depending on surveillance type)	AU\$46,423–44,386	±25%	Gamma	Goldsbury et al. ⁴² and Kastrinos et al. ⁵⁶
Cost per CRC case in the continuing phase (annually)	AU\$5998–4200	±25%	Gamma	Goldsbury et al. ⁴²
Cost per EC case in the initial phase (first year)	AU\$30,638	±25%	Gamma	Goldsbury et al. ⁴²
Cost per EC case in the continuing phase (annually)	AU\$4773	±25%	Gamma	Goldsbury et al. ⁴²
Cost per fatal cancer case	AU\$62,205	±25%	Gamma	Goldsbury et al. ⁴²
Cost of hysterectomy	AU\$12,124	±25%	Gamma	Lynch Syndrome Australia ¹⁹
Cost per gastrointestinal bleeding hospitalisation	AU\$60,769	±25%	Gamma	Roberts et al. ⁵⁷
Utility weight CRC	0.76	0.699–0.823	Beta	Farlikka et al. ⁵⁸
Utility weight post-CRC health state	0.85	±16% (SD)	Beta	Mulder et al. ⁵⁹
Utility weight EC	0.83	±0.02 (SE)	Beta	Ferguson et al. ⁶⁰
Utility weight post-EC health state	0.88	±0.02 (SE)	Beta	Ferguson et al. ⁶⁰
Familial hypercholesterolemia (FH) (screening for the LDLR, APOB and PCSK9 genes)				
Population prevalence of LDLR, APOB and PCSK9 pathogenic variants (PV)	0.004	0.0029–0.0052	Log-normal	Akiyamen et al. ⁸
Risk of first CHD event	Age- and sex-specific	±15%	Log-normal	Versmissen et al. ¹⁶
Proportion of fatal CHD	0.129	±15%	Log-normal	Jorstad et al. ⁶¹
Risk of recurrent CHD	Age- and sex-specific	±15%	Log-normal	Steg et al. ⁶²
Reduction of CHD risk with statins (HR)	0.24	0.18–0.30	Log-normal	Versmissen et al. ¹⁶
Cost of non-fatal CHD	AU\$11,047	±25%	Gamma	AR-DRG ³⁴
Chronic costs post-CHD (annually)	AU\$5620	±25%	Gamma	Cobiac et al. ⁶³
Statin treatment costs (annually)	AU\$253	±25%	Gamma	PBS ⁵⁵
Statin adherence in individuals with a genetic diagnosis of FH	79%	±15%	Log-normal	Luirink et al. ⁶⁴
Statin adherence in individuals prescribed statins from the general population (without a genetic diagnosis of FH)	50%	±15%	Log-normal	Talic et al. ⁶⁵
Utility weights for “Alive, with CHD”	0.80	0.57–1.00	Beta	Lewis et al. ⁶⁶
Utility weights for an acute CHD event	0.71	0.41–1.00	Beta	Lewis et al. ⁶⁶
Abbreviations: PV, pathogenic variant; BC, breast cancer; OC, ovarian cancer; RRM, risk-reducing mastectomy; RRSO, risk-reducing salpingo-oophorectomy; HR, hazard ratio; CHD, coronary heart disease; MRI, magnetic resonance imaging; CRC, colorectal cancer; iFOBT, immunochemical fecal occult blood test; EC, endometrial cancer; RRH, risk-reducing hysterectomy; RR, relative risk; AU\$, Australian dollars; SD, standard deviation; SE, standard error; MBS, Medicare Benefits Schedule; MSAC, Medical Services Advisory Committee; AR-DRG, Australian Refined Diagnosis-Related Groups; AIHW, Australian Institute of Health and Welfare; PBS, Pharmaceutical Benefits Scheme. All costs are presented in 2021 AU\$.				

Table 1: Model inputs for the base case, distributions and data sources.



Abbreviations: mgrm, mammogram; MRI, magnetic resonance image; CHD, coronary heart disease; BC, breast cancer; OC, ovarian cancer; CRC, colorectal cancer; EC, endometrial cancer. Details regarding transition probabilities and risk reduction strategies are presented in **Supplementary Materials**.

Fig. 2: Markov models. Markov models were created for: **a)** Female *BRCA1* and *BRCA2* pathogenic variant carriers, capturing outcomes for breast and ovarian cancer; **b)** male *MLH1* and *MHS2* carriers, capturing outcomes for colorectal cancer; **c)** female *MLH1* and *MHS2* carriers, capturing outcomes for colorectal cancer and endometrial cancer; and **d)** *LDLR*, *PCSK9* and *APOB* carriers, capturing outcomes for coronary heart disease.

interval (CI) of 0.032–0.53).^{20,41,69} Further risk-reducing strategies included RRBM (assumed uptake of 60% at an age of 40 years; breast cancer HR of 0.061 with a 95% CI of 0.02–0.20³⁸) and RRSO (assumed uptake of 78% at an age of 45 years³⁸; ovarian cancer HR of 0.21 with a 95% CI of 0.12–0.39). The impacts on cancer-specific mortality and remission were also estimated (see the **Supplementary Materials**). Routine breast-cancer surveillance was assumed in undetected PV carriers (age of biennial mammograms of 50–74 years; 54% uptake; breast cancer HR of 0.75 with a 95% CI of 0.69–0.81).^{40,70} No ovarian-cancer screening was modelled (no screening options are currently available).

For LS, we estimated outcomes for colorectal cancer in men, and colorectal and endometrial cancer in women. The risk of colorectal cancer in PV carriers versus the general population was estimated using age- and sex-specific hazard ratios,⁴⁹ modified by surveillance strategies. The impact of surveillance on remission and mortality risk was modelled.⁷¹ All undetected PV carriers were assumed to have access to standard bowel cancer screening from age 50 years (i.e. biennial immunochemical fecal occult blood test (iFOBT), uptake: 45% for women and 42% for men, with colonoscopy following positive result).⁵² Detected high-risk PV carriers were assumed to undergo intensive surveillance (annual colonoscopy, 15% reduction in incidence and mortality) and chemoprevention (daily aspirin, 40% reduction in incidence) from an age of 25 years⁴⁹ (accounting for the excess risk of gastrointestinal bleeding due to aspirin⁵¹). Lifetime rather than annualized risk of endometrial cancer was estimated in female *MLH1* and *MHS2* PV carriers⁶ owing to the lack of age-specific data. Risk-reducing hysterectomy (RRH) was assumed to have a 62% uptake at an age of 45 years⁷² in women.

For FH, estimates of age- and sex-specific CHD risk and risk-reducing strategies have been validated and published previously.²⁴ Briefly, this included annualized risk estimates for incident CHD,¹⁶ risk of recurrent CHD,⁶² and risk reduction strategies for CHD using cholesterol-lowering statins (CHD HR of 0.24, 95% CI 0.18–0.30).¹⁶ We assumed statin adherence rates of 79% for individuals following a genetic diagnosis of FH⁶⁴ (identified either by population genomic screening or clinical criteria-based genetic testing) and 49.0% for individuals prescribed statins from the general population for any other reason.⁶⁵

Utility scores and costs

Utility scores (values associated with a given health state, with values ranging from 0 to 1) (Table 1) were derived from the literature and originally extracted using the EuroQol 5 dimensions 5 levels questionnaire (EQ-5D-5L).⁷³ For all models, age- and sex-specific utility scores for the “disease free” health state were extracted from a cross-sectional Australia-specific study ($n = 2900$ healthy individuals) measuring quality-of-life scores for the general population.³⁵ The costs for each specific health state and for all acute events, procedures and adverse events are collated in Table 1 and presented in detail in the **Supplementary Materials**.

For Strategy 1 (status-quo arm of the model), the cost of clinical-criteria-based genetic testing was set at AU\$1200, equivalent to the current reimbursement rate for publicly funded criteria-based-genetic testing of each of these conditions in Australia³³ (Medicare Benefits Schedule Items 73,296 [HBOC], 73,354 [LS] and 73,352 [FH]). In the intervention arm (Strategy 2, population genomic screening), we assumed a cost per test of AU\$200 (~£115/€130/US\$140) for the

combined testing of all three conditions. This was the cost that was varied in the scenario analyses (AU\$50–AU\$1200).

The cost per test of AU\$200 was selected based on the current approximate cost of delivering the same type of testing (for the same genes) to a pilot study population of 10,000 adults in Australia, in a research setting.¹⁷ The cost includes postal saliva DNA collection nationwide, laboratory sample processing and DNA extraction, library preparation, targeted DNA sequencing using a custom panel of high-risk genes, data analysis and sample storage fees in Australia. The gene list used in the model does not include any moderate-risk genes. All acute and chronic costs for each model were derived from published sources. All costs were Australian specific and are presented in 2022 AU\$. If costs were derived from previous years, the Australian health price index was used to adjust for inflation. All costs are available in [Table 1](#) and [Supplementary Materials](#).

Scenario and sensitivity analyses

We performed scenario and sensitivity analyses to test the effect of varying key input parameters and the internal reliability of the models. In the scenario analyses, we tested variations in: a) the discount rate (0–6%); b) the cost per test for Strategy 2 (AU\$50–AU\$1200); c) the age range of the selected population (18–40, 18–50 and 25–50 years); and d) adopting a societal perspective, including productivity losses using the human-capital approach (estimating indirect costs due to reduced productivity and accounting for foregone future earnings).⁷⁴ Scenario analyses for each separate model are presented in the [Supplementary Materials](#).

We performed one-way sensitivity analyses to determine the key drivers of cost-effectiveness in each model separately, using the upper and lower range presented for each input parameter in [Table 1](#). A probabilistic sensitivity analysis was also run using 10,000 Monte Carlo simulations, using the distributions of each input parameter rather than the point estimates. Distributions for each parameter are also presented in [Table 1](#). The model was built using Microsoft Excel (2016) and sensitivity analyses were performed with @Risk (version 7.6) and R software (4.3.1). This study followed the 2022 Consolidated Health Economic Evaluation Reporting Standards⁷⁵ ([Appendix 6](#), [Supplementary Materials](#)).

Ethics

This health-economic evaluation is part of the *DNA Screen* project, approved by the Alfred Hospital Research Ethics Committee (Project #597/21). Participant informed consent was not required for this study type.

Role of the funding source

Funders had no role in the study design; collection, analysis, and interpretation of data; writing of the report;

or decision to submit for publication. All authors confirm that they had full access to all the data in the study and accept responsibility for the decision to submit for publication.

Results

Base-case analysis

Over the lifetime of the modelled population and compared with the status quo of criteria-based genetic testing, the alternative strategy of combined population genomic screening for the three high-risk conditions (followed by subsequent interventions) was estimated to prevent 2612 cancer cases (1140 breast, 950 ovarian, 451 colorectal and 71 endometrial), 542 non-fatal CHD events and 4047 deaths due to cancer and/or CHD ([Table 2](#)). Per-100,000 individuals screened, this would result in the prevention of 63 cancer cases, 31 CHD cases and 97 deaths. Offering genomic screening and subsequent interventions to the modelled population would lead to 20,553 extra years of life lived and 31,094 extra QALYs, compared to the status quo. Per-100,000 individuals screened, this would result in 494 extra years of life lived and 747 extra QALYs.

With an assumed per-test cost of AU\$200 for combined genomic screening, the cost of offering testing alone to the modelled population, assuming a 50% testing uptake rate, would be AU\$832 million above current estimated expenditure on genetic testing in Australia (assumed as an up-front single cost in the first annual cycle of the model). Offering genomic screening would then incur a further AU\$282 million in additional direct healthcare costs related to ongoing surveillance and risk-management of identified PV carriers (itemized in [Table 2](#)). This includes an assumed AU\$539 per PV carrier for clinical confirmation testing and post-test genetic counseling.

However, the resulting savings through early detection or prevention of cancer and heart disease achieved by genomic screening would exceed AU\$394 million, including AU\$198.97 million saved on chronic CHD costs, AU\$72.99 million saved on cancer treatments, and AU\$15.54 million of savings related to death. Given the total estimated net cost of genomic screening to the modelled population (AU\$825.54 million), this translates into a cost-effective ICER in the Australian healthcare system of AU\$36,252/YLL and AU\$23,963/QALY gained (well below the established willingness-to-pay [WTP] threshold of AU\$50,000/QALY gained⁶⁷) ([Table 3](#)). Threshold analysis indicated that cost-effectiveness would be maintained under this threshold for per-test costs up to AU\$325.

Scenario analyses

In the scenario analyses ([Table 3](#)), we investigated the impact of modifying the age range of individuals to whom population genomic screening would be offered

Total screened population = 4,162,121	Status quo (comparator)	Population genomic screening (intervention)	Difference (intervention versus comparator)	Per 100,000 screened
BC cases	10,405	9265	-1140	-27
OC cases	3712	2762	-950	-23
CRC cases	4438	3987	-451	-11
EC cases	629	557	-71	-2
All cancer cases	19,184	16,571	-2612	-63
Cancer deaths	3631	2691	-939	-23
Non-fatal CHD cases	40,213	39,071	-542	-13
CHD deaths	17,931	17,172	-759	-18
All CHD cases	58,144	56,843	-1300	-31
Total deaths (CHD and cancer)	21,561	17,514	-4047	-97
YLL	1,178,463	1,199,778	20,553	494
QALYs	1,002,194	1,034,265	31,094	747
Genetic testing costs	\$6,934,303	\$832,481,750	\$825,547,447	\$419,727
Genetic counseling costs	\$3,130,249	\$20,599,795	\$17,469,546	-\$629,260
Acute CHD costs	\$249,770,917	\$223,580,344	-\$26,190,573	-\$4,780,513
Chronic CHD costs	\$1,492,933,141	\$1,293,962,392	-\$198,970,749	\$576,590
Lipid-lowering treatment costs	\$70,090,603	\$94,088,965	\$23,998,362	\$1,317,209
Risk reduction surgeries costs	\$13,705,954	\$68,529,772	\$54,823,818	\$1,342,019
High-risk surveillance for BC	\$16,170,573	\$72,027,045	\$55,856,472	\$1,922,736
High-risk surveillance for CRC	\$15,981,044	\$96,007,655	\$80,026,611	\$25,909
Gastrointestinal bleeding costs	\$269,587	\$1,347,933	\$1,078,346	-\$1,753,892
Cancer treatment costs	\$461,239,708	\$388,240,605	-\$72,999,103	-\$373,491
Death costs	\$88,069,538	\$72,524,410	-\$15,545,128	\$419,727
Healthcare costs ^a	\$2,411,361,314	\$2,330,908,916	-\$80,452,398	-\$1,932,966
Total costs (with PGS)			\$745,095,048	\$17,901,811
ICER (cost/YLL)			\$36,252	
ICER (cost/QALY)			\$23,963	

Abbreviations: CHD, coronary heart disease; BC, breast cancer; OC, ovarian cancer; CRC, colorectal cancer; EC, endometrial cancer; YLL, years of life lived; QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio. For detailed results in each individual model, see the Supplementary Materials. ^aIncludes all healthcare costs except the cost of PGS.

Table 2: Main health, economic results and cost-effectiveness results for the base-case analysis from the combined model.

from 18–40 years (base case) to 18–50 years and 25–50 years. The ICERs for these age ranges (compared with the status-quo arm of no genomic screening) were also cost-effective well under the WTP-threshold, with an ICER of \$21,299/QALY for the 18–50-year-old group and \$28,317/QALY for the 25–50-year-old group. When the different age groups were compared against the base case, the base case (i.e. genomic screening for 18–40 years old) resulted in the dominant strategy, yielding higher costs and higher QALYs gained (Table 4).

When considering each model independently using the base-case settings, we found that offering genomic screening for FH alone was cost-effective (ICER of AU\$40,016/QALY), whereas screening for HBOC alone (ICER of AU\$136,658/QALY) or LS alone (ICER of AU\$382,396/QALY) would not be cost-effective in the same modelled population. For detailed results of the individual models, see the Supplementary Materials).

From a societal perspective, using the human-capital approach and considering productivity costs due to the

Scenario	ICER (AU\$/YLL)	ICER (AU\$/QALY)
Base case	\$36,252	\$23,963
Increasing population genomic screening uptake to 75% (base case 50%)	\$46,871	\$31,360
Annual discount rate 0% (base case 5%)	\$3972	\$1263
Annual discount rate 3% (base case 5%)	\$7401	\$4758
Cost per test AU\$50 (base case AU\$200)	\$5874	\$3883
Cost per test AU\$100 (base case AU\$200)	\$16,000	\$10,576
Cost per test AU\$500 (base case AU\$200)	\$97,007	\$64,123
Cost per test AU\$1200 (base case AU\$200)	\$238,769	\$157,830
Age range 18–50 years (base case 18–40)	\$31,825	\$21,299
Age range 25–50 years (base case 18–40)	\$43,175	\$28,317
Societal perspective (including indirect costs using the human-capital approach)	Dominant ^a	Dominant ^a

^aDominant ICERs represent cost-saving results.

Abbreviations: ICER, incremental cost-effectiveness ratio; YLL, years of life lived; QALY, quality-adjusted life year.

Table 3: Results from scenario analysis for the combined model.

	Age-group screened (years)			Versus 18–40 years	Versus 18–40 years
	18–40	18–50	25–50	18–50	25–50
Years of life lived	20,553	20,687	16,441	134	-4112
QALYs	31,093	30,911	25,068	-182	-6026
Total costs	\$739,543,763	\$658,374,583	\$709,864,422	-\$81,169,180	-\$29,679,341
ICER (cost/QALY)				Dominated	Extended dominated

Abbreviations: ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.

Table 4: Results from the cost-effectiveness of independent ranking for the population genomic screening of different age groups.

increased morbidity and mortality in individuals with HBOC/LS/FH variants, at AU\$200 per test, the intervention of population genomic screening would be cost saving (dominant ICER individually) versus the status quo (Table 3). Scenario analyses showed that if the per-test cost was increased to AU\$325 per test, genomic screening would still be cost-effective below the AU\$50,000/QALY WTP threshold. However, at AU\$500 per test, the ICER would no longer be cost-effective (AU\$64,123/QALY) with 5% annual discounting.

Lowering the discount rate of the base case from 5% to 3% (at AU\$200 per test) had a major impact on the model results. The ICER for combined genomic screening using a 3% annual discount rate lowered from AU\$23,963/QALY (5% discounting rate, base case) to AU\$4758/QALY (3% discounting rate,


scenario analysis). The 3% discounting rate is the most common rate in jurisdictions other than Australia.

Sensitivity analyses

Results from a one-way sensitivity analysis (Fig. 3) indicated that all input variations in the base case model (assuming AU\$200 per test and combined genomic screening for HBCO/LS/FH) led to an estimated ICER under the cost-effectiveness threshold of AU\$50,000/QALY gained. Results from probabilistic sensitivity analysis (Fig. 4) demonstrate the improved cost-effectiveness of combined screening, and indicate that in the base-case analysis (AU\$200 per test), combined genomic screening would be cost-effective under 70% of simulations, cost-saving under 25% and not cost-effective under 5% (Fig. 4b).

Discussion

Our model of combined population genomic screening estimated the prevention of thousands of cancers, heart disease cases and deaths in high-risk individuals aged 18–40 years in the general Australian population. Currently, the vast majority of these high-risk individuals are not being identified by the status quo of clinical criteria-based genetic testing. Our model indicated that the intervention of genomic screening, if offered at AU\$200 per test, would be cost-effective in the Australian public healthcare system, yielding an ICER of AU\$23,963/QALY gained over the status quo. In scenario analysis using a 3% discounting rate, the ICER reduced further to AU\$4758/QALY. Currently in



Abbreviations: CHD, coronary heart disease; CRC, colorectal cancer; RRSO, risk reducing salpingo-oophorectomy; BC, breast cancer; RRM, risk reducing mastectomy; ICER, cost-effectiveness ratio; QALY, quality-adjusted life year.

Fig. 3: One-way sensitivity analysis. The incremental cost-effectiveness ratio (ICER) for the base-case of the combined model was AU\$20,734/quality-adjusted life year (QALY) gained. Results of one-way sensitivity analysis for all input variations led to ICERs under the AU\$50,000/QALY willingness-to-pay threshold. These ICERs ranged between AU\$15,000–\$25,000/QALY gained. Low-limit ICER estimates are shown in blue and upper-limit ICER estimates are shown in orange.




Fig. 4: Probabilistic sensitivity analysis. Results for the base case of the model (AU\$200 per sample) are shown for: **a)** individual condition Markov models separately (hereditary breast and ovarian cancer in red, Lynch syndrome in green, familial hypercholesterolemia in blue), and **b)** the combined model (all three conditions together in black). Results are presented as incremental costs (x-axis) per carrier versus incremental effect (y-axis) per carrier. The diagonal black line indicates the AU\$50,000 per quality-adjusted life year (QALY) willingness-to-pay threshold or cost-effectiveness plane.

Australia, clinical genetic testing for either HBOC, LS or FH individually (for patients who meet strict eligibility criteria) is reimbursed at a fee of AU\$1200 per test.³³ Threshold analysis indicated that the alternative detection strategy of population genomic screening for these conditions would need to be deliverable at AU\$325 per test (or lower) to be considered cost-effective in the Australian public healthcare system, below the AU\$50,000 willingness-to-pay (WTP) threshold with 5% discounting. Internationally, clinical-grade tests from commercial providers are now available for AU\$280–AU\$450, and other studies have also modelled genomic screening using a US\$200 per-test cost,^{27–29} indicating these price ranges are now achievable. In the future, prices may fall further, making the prospect of genomic screening even more cost-effective and feasible.

Previous modeling studies of population genomic screening for individual conditions (e.g. HBOC and FH) have indicated potential cost-effectiveness in countries with a national public healthcare system, including Australia^{23,24} and the UK.^{25,26} However, our study suggests there would be an improvement in the overall cost-effectiveness and efficiency of genomic screening, if offered in a combined fashion for multiple conditions together, for example screening for hereditary cancer predisposition syndromes and FH concurrently (assuming the per-test cost can be maintained, which is possible with current sequencing technology). This combined approach to genomic screening is supported by recent modelling by Guzauskas et al. in the US, demonstrating that cost-effectiveness is improved by combined screening of HBOC, LS and FH in individuals aged 30 years in a US health system.³¹

There are several important differences between our study and that of Guzauskas et al. The two studies are based on fundamentally different healthcare systems in

different countries (Australia versus the US), which vary by structure, reimbursement methods, costs and participation rates. In particular, the amount of baseline screening, detection and participation in these healthcare systems (as represented in standard-of-care model arms) vary greatly. The two studies used different source of inputs and model parameters and settings. The model of Guzauskas et al. includes cascade testing in the final ICER calculation, whereas our model does not. This is likely to have a considerable bearing on overall cost-effectiveness, given that, on average, cascade testing can identify up to three more high-risk individuals per family identified.²⁰ Guzauskas et al. applied a 3% discounting rate (versus 5% in our study) and modelled testing at US\$250 per-sample (~AU\$390) versus our figure of AU\$200. Guzauskas et al. also modelled genomic screening at a single timepoint (cohort of 30-year-olds) in the base-case, rather than an age-range (e.g. 18–40-year-olds). The WTP used in Australian studies (AU\$50,000 or ~US\$38,750 per QALY) is considerably lower than the US WTP of US\$100,000 (or ~AU\$147,000) per QALY. These and other differences make the direct comparison of results from the two studies complicated. Ultimately, both studies estimated that offering population genomic screening in two different healthcare systems for the same three conditions would be cost-effective for young adults (ICERs of US\$68,600/QALY versus AU\$23,580/QALY for the respective base-cases).

In our model of the Australian national public healthcare system, we observed a higher proportional impact of FH and cardiovascular prevention (relative to cancer prevention) than in the model of Guzauskas et al. Although there are several possible explanations for this, our hypothesis is that baseline cancer screening and prevention in Australia (in the status-quo arm) may be

higher than the US, largely due to the established and implemented national population-based cancer screening programs in Australia (e.g. breast cancer and bowel cancer screening, available to all adults aged 50–74 years). This baseline difference in cancer screening and prevention in Australia may mean that the incremental impact of adding population genomic screening may be lower in Australia than in the US for cancer, relative to the status quo.

In Australia, there is a national public healthcare system with a proven ability to deliver population-based screening programs that are funded by the Australian Government and guided by the established national Population-Based Screening Framework. Under these circumstances, the prospect of implementing a national DNA-based population screening program is feasible in Australia. The ICER for the base case of our model (AU\$23,963/QALY-gained or AU\$36,252/YLL) suggests that the cost-effectiveness of offering a population genomic screening program to 18–40 year-olds would be comparable to existing population-based screening programs in Australia. For example, recent modeling of existing Australian population-based cancer screening programs⁷⁶ estimated ICERs ranging from AU\$3380 to AU\$65,065 per life-year saved (LYS, a comparable measure to YLL). The national breast screening program (BreastScreen Australia) offers biennial mammography to 50–69-year-old women (ICER of \$40,279–65,065/LYS). The National Cervical Screening Program offers 5-yearly human papillomavirus testing for 25–74-year old women (ICER of AU\$16,632/LYS). The National Bowel Cancer Screening Program offers biennial fecal occult blood testing to 50–75-year-old men and women (ICER of AU\$3380/LYS). Thus, offering combined genomic screening for the conditions modelled in our analyses (ICER of AU\$31,196/YLL) would fit within the acceptable cost-effectiveness range of these programs. From a societal perspective, considering the broader economic impacts on workforce productivity and other factors, our modelling suggested that genomic screening would be cost saving (i.e. dominant strategy) in the Australian system. This result is supported by other cost-effectiveness analyses of genomic screening in other western health systems,²⁶ using a societal perspective for reimbursement policies.

The optimal age range to offer genomic screening must be considered carefully by policy makers. Other studies have shown that offering genomic screening to all women aged >18 years (with no upper age limit) for the *BRCA1* and *BRCA2* genes would be cost-effective.^{25,26} These studies are supported by evidence of feasibility, acceptability and satisfaction among research participants.^{77,78} Factors beyond the age-range of genomic screening also need to be considered in the overall assessment. For example, the allocative efficiency and maximization of consumer benefits that are not

financially quantifiable must be considered. This includes implications for reproductive decision making, variability in uptake rates, and differing views of “medical actionability” among different societal and age groups. The potential anxiety experienced by very young adults when receiving cancer risk information between the ages of 18 and 25 years (when high-risk surveillance may not commence until the age of 30 years), must be balanced against preventive benefits, including reproductive implications. For FH, commencement of cholesterol-lowering treatment is typically recommended directly after a genetic diagnosis, even for children, making early PV detection a priority.

Further ethical and societal issues must be also considered. We highlight the need for more public education and awareness of genomics in society, as well as an appropriate informed-consent framework for population genomic screening to discuss potential benefits and harms, and the need to protect high-risk individuals against genetic discrimination. From a resourcing perspective, providing timely access to downstream clinical care, risk management and genetic counseling services is a major implementation challenge and potential barrier. Further research and piloting are required to understand the full itemization of costs and associated services that would be required to support genomic screening, including programmatic delivery, overheads, genetic counselling, clinical geneticist and other specialist care, and staffing requirements associated with implementing a screening program in a national healthcare system. These costs and services will vary between countries and healthcare systems.

There is no consensus on which conditions (or genes) should be included in population genomic screening. Previous modeling studies have focused on cancer genes and mostly in women.^{18,25,26,29} Our model focuses on three high-risk, medically actionable genomic conditions and expands screening to include cardiovascular disease (FH) genes and includes men. Although some guidance on genomic screening is emerging,^{3,79} we included only individual “Tier 1” genomic applications designated by the US CDC.² There is an emerging need to develop more evidence-based approaches for the consideration of additional conditions and genes in population genomic screening initiatives, including the possible use of positive predictive value as a more agnostic approach.⁸⁰ An extended gene panel for (moderate to high penetrance) HBOC genes has been shown to be cost-effective in women in the UK and USA.²⁵ While acknowledging that other genes and conditions deserve consideration for population screening, we note the inclusion of lower-penetrance genes and moderate risk conditions may shift the overall cost-effectiveness. Future modeling may consider this question. Our model assumed variants of uncertain significance (VUS) would not be returned in

population screening. We acknowledge the complexity of returning VUS, and that different approaches are being taken internationally.^{21,22}

Strengths of our study include the detailed modeling and use of annualized age- and sex-adjusted risk data, and Markov models across five different disease outcomes (breast, ovarian, colorectal, endometrial cancer and coronary heart disease) and three genomic conditions. We used model inputs based on published studies and sought expert clinical advice for each disease model. Our modelling is timely due to the recent introduction of the Australian Government-funded *DNA Screen* national pilot study, which is currently offering population genomic screening to 10,000 represented adults aged 18–40 years in Australia for the same conditions modelled.¹⁷ Our findings are therefore of immediate relevance to future Australian health policy considerations and directly comparable to a real-world pilot study of the same target population and demographic.

Limitations of our study include the assumptions made about uptake of genetic screening (50% in the base case) and the sensitivity and specificity of genomic testing (100%). We acknowledge that the uptake of population genomic screening in Australia is untested. We assumed 50% uptake, which is consistent with the uptake of existing population-based screening programs in Australia.⁷⁶ Our model did not include the *PALB2* and *MSH6* genes, or moderate-risk HBOC genes, which are often included on expanded gene panels.²⁵ We excluded the *PMS2* gene (for Lynch syndrome) from both our model and the *DNA Screen* pilot study, as the gene was deemed to be of insufficient penetrance to warrant inclusion in population screening. Our study did not assess public perceptions and preferences, patient-reported outcomes or experience measures, or explore issues related to equity and access. Whilst our model accounted for some additional costs incurred by population genomic screening, such as clinical confirmation testing and post-test genetic counseling (AU\$539), it is likely that further hidden costs exist within the system and have not been accounted for, including potential costs related to workforce expansion, public education, recruitment, programmatic staffing and laboratory overheads. We acknowledge there is uncertainty around the uptake rates, adherence and compliance to recommended interventions for high-risk individuals once identified, and potential hidden costs for downstream clinical services and interventions for these individuals, including complications related to risk-reducing surgeries or colonoscopies. We did not consider in detail how genomic screening would interface with other population screening programs, including the national breast cancer and bowel cancer screening programs in Australia.

For simplicity, our model assumed that genomic screening was offered in the first annual cycle of the model (as an up-front single cost) rather than amortized

over the decades required to implement a screening program. The model did not distinguish between early- and late-stage cancers, considering all to be equally invasive with an averaged treatment cost.³⁷ We assumed equivalence of future disease risk (i.e. gene penetrance) in PV carriers ascertained either clinically^{6,7,16} or by population screening. We acknowledge there may be differences in penetrance based on ascertainment method, genetic diversity or ancestry, with gaps remaining in evidence. Although early gene-penetrance estimates from the general population may be lower than in clinically-ascertained cohorts^{36,81} it is likely that for the high-risk genes included in our model, there will still be sufficiently high positive predictive value upon PV detection to warrant intervention and risk management, even with reduced penetrance. For the purposes of our model, we used penetrance estimates only from highly-cited epidemiological studies^{6,7,16} and applied $\pm 15\%$ confidence ranges to all risk estimates to address this uncertainty.

There is an emerging public health opportunity to offer adult population genomic screening to improve the early detection and prevention of cancer and heart disease caused by high-risk inherited monogenic conditions. Our modelling demonstrates a marked improvement in the overall cost-effectiveness of offering population genomic screening in a combined fashion for multiple conditions together, versus criteria-based clinical genetic testing or screening for individual conditions. The model structure can be applied to other healthcare systems, making our findings relevant for international jurisdictions, especially countries with national public healthcare systems capable of delivering nation-wide population screening programs.

Contributors

PL conceived the study. PL, CM, JT and ZA designed the study, reviewed the literature, collected data, interpreted the results and wrote the manuscript. CM led the modelling analyses, with supervision from ZA, who together generated results, wrote code and developed figures. CM and ZA verified the underlying data. AB, KN, YJK, MM, RM, KC and JJM provided epidemiological and methodological oversight. Clinical expertise was provided by RCG, RM, GF, PJ, IW and JM. All co-authors provided critique and/or review of the manuscript. PL and ZA are responsible for the overall content as guarantors. All authors confirm that they had full access to all the data in the study and accept responsibility for the decision to submit for publication.

Data sharing statement

Model available upon request from the corresponding author.

Declaration of interests

RM. declares advisory board membership from AstraZeneca/MSD/EGL/GSK. RCG. has received compensation for advising Allelica, Fabric, GenomeWeb, Genomic Life and Verily; and is a co-founder of Genome Medical and Nurture Genomics. KC. is co-Principal Investigator (PI) of an investigator-initiated trial of cervical screening, Compass, run by the Australian Centre for Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity; the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, and operational support from the Australian Government. KC. is also co-PI on a major investigator-initiated

implementation program Elimination of Cervical Cancer in the Western Pacific (ECCWP) receives support from the Minderoo Foundation and equipment donations from Cepheid Inc. No other authors declare competing interests.

Acknowledgements

The authors thank the study funders including the Australian Government, Department of Health, Medical Research Future Fund, Genomics Health Futures Mission (APP2009024) and the National Heart Foundation of Australia (102604).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.eclinm.2023.102297>.

References

- 1 Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. *N Engl J Med*. 2003;348(1):50–58.
- 2 Murray MF, Evans JP, Khoury MJ. DNA-based population screening: potential suitability and important knowledge gaps. *JAMA*. 2020;323(4):307–308.
- 3 Murray MF, Giovanni MA, Doyle DL, et al. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(6):989–995.
- 4 Grzymalski JJ, Elhanan G, Morales Rosado JA, et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. *Nat Med*. 2020;26(8):1235–1239.
- 5 Buchanan AH, Lester Kirchner H, Schwartz MLB, et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. *Genet Med*. 2020;22(11):1874–1882.
- 6 Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2017;26(3):404–412.
- 7 Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA*. 2017;317(23):2402–2416.
- 8 Akiyama LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. *BMJ Open*. 2017;7(9):e016461.
- 9 eMERGE Clinical Annotation Working Group. Frequency of genomic secondary findings among 21,915 eMERGE network participants. *Genet Med*. 2020;22(9):1470–1477.
- 10 Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA*. 2010;304(9):967–975.
- 11 Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst*. 2009;101(2):80–87.
- 12 Crosbie EJ, Flaum N, Harkness EF, et al. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. *Int J Cancer*. 2021;148(5):1155–1163.
- 13 Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011;378(9809):2081–2087.
- 14 Manchanda R, Saridogan E, Abdelrahman A, et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). *Arch Gynecol Obstet*. 2012;286(6):1555–1562.
- 15 Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. *Heart Lung Circ*. 2021;30(3):324–349.
- 16 Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ*. 2008;337:a2423.
- 17 Lacaze PA, Tiller J, Winship I, DNA Screen Investigator Group. Population DNA screening for medically actionable disease risk in adults. *Med J Aust*. 2022;216(6):278–280.
- 18 Manchanda R, Blyuss O, Gaba F, et al. Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. *J Med Genet*. 2018;55(8):538–545.
- 19 Australia LS. *Misdiagnosed, misunderstood and missing out: Lynch syndrome Australia's untold health story*; 2017. <https://lynchsyndrome.org.au/wp-content/uploads/2017/03/Lynch-Syndrome-Report.pdf> (viewed Dec 2021).
- 20 Rowley SM, Mascarenhas L, Devereux L, et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. *Genet Med*. 2019;21(4):913–922.
- 21 Lacaze P, Manchanda R, Green RC. Prioritizing the detection of rare pathogenic variants in population screening. *Nat Rev Genet*. 2023;24(4):205–206.
- 22 Manchanda R, Sideris M. Population-based genetic testing for cancer susceptibility genes: quo vadis? *BJOG*. 2023;130(2):125–130.
- 23 Zhang L, Bao Y, Riaz M, et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. *Genet Med*. 2019;21(9):1958–1968.
- 24 Marquina C, Lacaze P, Tiller J, et al. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. *Eur Heart J*. 2022;43(34):3243–3254.
- 25 Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. *J Natl Cancer Inst*. 2018;110(7):714–725.
- 26 Manchanda R, Sun L, Patel S, et al. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems. *Cancers (Basel)*. 2020;12(7):1929.
- 27 Guzauskas GF, Jiang S, Garbett S, et al. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. *Genet Med*. 2022;24(5):1017–1026.
- 28 Spencer SJ, Jones LK, Guzauskas GF, et al. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. *J Clin Lipidol*. 2022;16(5):667–675.
- 29 Guzauskas GF, Garbett S, Zhou Z, et al. Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States. *JAMA Netw Open*. 2020;3(10):e202874.
- 30 Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA. Towards population-based genetic screenings for breast and ovarian cancer: a comprehensive review from economic evaluations to patient perspectives. *Breast*. 2021;58:121–129.
- 31 Guzauskas GF, Garbett S, Zhou Z, et al. Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis. *Ann Intern Med*. 2023;176(5):585–595.
- 32 NSW Cancer Institute. *eviQ cancer treatments online*; 2022. <https://www.eviq.org.au>.
- 33 Australian Government Department of Health and Aged Care. *Medicare Benefits Schedule (MBS)*. *MBS Online*; 2023 [cited 2023 Feb 17]. Available from: <http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home>.
- 34 Australian Institute of Health and Welfare. *Australian refined diagnosis-related groups (AR-DRG) data cubes*. *Data cubes*. Australian Institute of Health and Welfare; 2019 [cited 2020 Jun 30]. Available from: <https://www.aihw.gov.au/reports/hospitals/ar-drg-data-cubes/contents/data-cubes>.
- 35 McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. *Health Qual Life Outcomes*. 2016;14(1):133.
- 36 Van Hout CV, Tachmazidou I, Backman JD, et al. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature*. 2020;586(7831):749–756.
- 37 Australian Institute of Health and Welfare. *Cancer data in Australia*. Australian Institute of Health and Welfare; 2023 [cited 2023 Feb 17]. Available from: <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/about>.
- 38 Marcinkute R, Woodward ER, Gandhi A, et al. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. *J Med Genet*. 2022;59(2):133–140.
- 39 Mytton J, Evison F, Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. *BMJ*. 2017;356:j372.
- 40 Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. *JAMA*. 2015;314(15):1615–1634.
- 41 Evans DG, Kesavan N, Lim Y, et al. MRI breast screening in high-risk women: cancer detection and survival analysis. *Breast Cancer Res Treat*. 2014;145(3):663–672.
- 42 Goldsbury DE, Yap S, Weber MF, et al. Health services costs for cancer care in Australia: estimates from the 45 and up study. *PLoS One*. 2018;13(7):e0201552.

- 43 Gordon LG, Scuffham PA, Beesley VL, et al. Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. *Int J Gynecol Cancer*. 2010;20(5):757–765.
- 44 Rautalin M, Farkkila N, Sintonen H, et al. Health-related quality of life in different states of breast cancer - comparing different instruments. *Acta Oncol*. 2018;57(5):622–628.
- 45 Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. *J Clin Oncol*. 2011;29(13):1664–1669.
- 46 Al-Dakkak I, Borrill J, Murphy E, Posnett J, Zhang Y. A systematic review of health state utility values for advanced ovarian cancer. *Value Health*. 2014;17(7):A645.
- 47 Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. *Clin Ther*. 2016;38(4):769–777.
- 48 Grann VR, Patel P, Bharthuar A, et al. Breast cancer-related preferences among women with and without BRCA mutations. *Breast Cancer Res Treat*. 2010;119(1):177–184.
- 49 Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *J Clin Oncol*. 2015;33(4):326–331.
- 50 Meiser B, Kaur R, Kirk J, et al. Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics. *Fam Cancer*. 2020;19(4):337–346.
- 51 Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med*. 2006;354(3):261–269.
- 52 Cancer Council Australia. *Bowel cancer screening | Cancer Council; 2023* [cited 2023 Feb 19]. Available from: <https://www.cancer.org.au/cancer-information/causes-and-prevention/early-detection-and-screening/bowel-cancer-screening>.
- 53 Australian Government Department of Health and Aged Care. *Bowel cancer screening; 2023* [cited 2023 Feb 19]. Available from: <https://www.health.gov.au/our-work/national-bowel-cancer-screening-program>.
- 54 Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. *Lancet*. 2020;395(10240):1855–1863.
- 55 *Australian Pharmaceutical Benefits Scheme (PBS); 2023* [cited 2023 Feb 19]. Available from: <https://www.pbs.gov.au/pbs/home>.
- 56 Kastrinos F, Ingram MA, Silver ER, et al. Gene-specific variation in colorectal cancer surveillance strategies for lynch syndrome. *Gastroenterology*. 2021;161(2):453–462.e15.
- 57 Roberts G, Baker M, Leiblich H, et al. Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis. *Intern Med J*. 2022;52(2):318–321.
- 58 Farkkila N, Sintonen H, Saarto T, et al. Health-related quality of life in colorectal cancer. *Colorectal Dis*. 2013;15(5):e215–e222.
- 59 Mulder F, van Roekel EH, Bours MJL, Weijenberg MP, Evers S. The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics. *J Cancer Surviv*. 2022;16(5):1055–1064.
- 60 Ferguson SE, Panzarella T, Lau S, et al. Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer. *Gynecol Oncol*. 2018;149(3):476–483.
- 61 Jorstad HT, Colkesen EB, Boekholdt SM, et al. Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. *Heart*. 2016;102(1):63–68.
- 62 Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. *JAMA*. 2007;297(11):1197–1206.
- 63 Cobiaci LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. *BMC Public Health*. 2012;12:398.
- 64 Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. *N Engl J Med*. 2019;381(16):1547–1556.
- 65 Talic S, Marquina C, Ofori-Asenso R, et al. Switching, persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data. *Cardiovasc Drugs Ther*. 2022;36(5):867–877.
- 66 Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). *JACC Heart Fail*. 2014;2(2):159–165.
- 67 Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. *Pharmacoeconomics*. 2018;36(2):239–252.
- 68 Australian Bureau of Statistics. *National, state and territory population, June 2020*. Australian Bureau of Statistics; 2021 [cited 2021 Oct 6]. Available from: <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release>.
- 69 NSW Cancer Institute. *BRCA1 or BRCA2 risk management; 2022* [cited 2022 Oct 28]. Available from: <https://www.eviq.org.au/cancer-genetics/adult/risk-management/3814-brca1-or-brca2-risk-management-female#>.
- 70 Australian Institute of Health and Welfare. *BreastScreen Australia monitoring report 2020. (Cancer series) Report No: 129 2020*. Australian Government; 2020.
- 71 Kang YJ, Caruana M, McLoughlin K, et al. The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. *Genet Med*. 2022;24(9):1831–1846.
- 72 Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. *J Clin Oncol*. 2007;25(33):5158–5164.
- 73 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727–1736.
- 74 van den Hout WB. The value of productivity: human-capital versus friction-cost method. *Ann Rheum Dis*. 2010;69(Suppl 1):i89–i91.
- 75 Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *Value Health*. 2022;25(1):3–9.
- 76 Lew JB, Feletto E, Wade S, et al. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. *Public Health Res Pract*. 2019;29(2):29121913.
- 77 Gaba F, Blyuss O, Liu X, et al. Population study of ovarian cancer risk prediction for targeted screening and prevention. *Cancers (Basel)*. 2020;12(5):1241.
- 78 Manchanda R, Burnell M, Gaba F, et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. *BJOG*. 2020;127(3):364–375.
- 79 Bean LJH, Scheuner MT, Murray MF, et al. DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(6):979–988.
- 80 Schiabor Barrett KM, Bolze A, Ni Y, et al. Positive predictive value highlights four novel candidates for actionable genetic screening from analysis of 220,000 clinicogenomic records. *Genet Med*. 2021;23(12):2300–2308.
- 81 Forrest IS, Chaudhary K, Vy HMT, et al. Population-based penetrance of deleterious clinical variants. *JAMA*. 2022;327(4):350–359.